Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
CVS Health is projecting another year of solid earnings growth, announcing that its expected 2026 profit will surpass both Wall Street forecasts and its own 2025 earnings outlook. The update, shared during the company’s investor day, underscores the steady progress of its ongoing turnaround strategy led by Chief Executive David Joyner.
Joyner emphasized that CVS has delivered on its commitments throughout the year and will now concentrate on improving consumer experiences and rebuilding trust—an area he described as a major challenge in today’s healthcare marketplace. As part of this effort, the company unveiled a new consumer app designed to integrate CVS services and offer new revenue opportunities for partners.
Shares of CVS climbed nearly 5% to $80.17 in morning trading following the announcement, extending a year of strong market performance. The stock has surged more than 70% in 2025 as the company implemented sweeping changes, including cost reductions, exits from underperforming markets, and enhancements to leadership to restore investor confidence.
Chief Financial Officer Brian Newman highlighted the company’s strong finish to 2025, stating that CVS expects “another year of strong earnings growth in 2026.” The company forecast adjusted earnings between $7.00 and $7.20 per share for 2026, slightly above consensus expectations of $7.16 per share.
While CVS anticipates up to $400 billion in revenue next year—short of analysts’ projected $419.26 billion—the company expects growth momentum to be driven by improved margins in its Aetna insurance arm and CVS Caremark pharmacy benefit management business. CVS also reiterated plans to exit the Affordable Care Act insurance market in 2026 due to rising medical costs.
Additionally, CVS raised its 2025 profit guidance to between $6.60 and $6.70 per share, marking its fourth increase this year. Analysts at Leerink Partners noted that CVS’ near-term performance supports a strong long-term recovery story for the healthcare conglomerate.
